Amanta Healthcare IPO will open on September 1 and close on September 3, 2025. Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company specialising in the development, manufacturing, and marketing of a wide range of sterile liquid products, primarily parenteral solutions.
This IPO update will cover the issue size, price band, financial performance, competitor analysis, and risk factors.
Amanta Healthcare IPO Date
The key pointers for the Amanta Healthcare IPO dates are:
- Bidding Opening Date: September 1, 2025
- Bidding Closing Date: September 3, 2025
- Allotment Date: September 4, 2025
- Initiation of Refunds (in case of less or no allotment): September 8, 2025
- Shares Credited to Your Demat Account: September 8, 2025
- IPO Listing Date: September 9, 2025
- Listing on Exchange: BSE and NSE
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Amanta Healthcare: IPO Issue Size
Amanta Healthcare IPO valuation, as denoted by the market capitalization, stood at ₹489.25 crores. Here are the important details:
- Amanta Healthcare IPO Price Band: ₹120 to ₹126 per share
- Lot Size: 119 Shares
- Total Issue Size and Amount: 1 crore shares (aggregating up to ₹126 crores)
- Fresh Issue Size and Amount: 1 crore shares (aggregating up to ₹126 crores)
Amanta Healthcare IPO Proceeds Usage
The net proceeds from the Amanta Healthcare IPO are proposed to be utilised for the following purposes:
1. Setting up a New SteriPort Manufacturing Line
- To cover the cost of civil construction and the purchase of equipment, plant, and machinery.
- Location: Hariyala, Kheda, Gujarat
- Estimated amount: ₹70 crores
2. Setting up a New SVP Manufacturing Line
- To fund civil construction and buy equipment, plant, and machinery for this new line.
- Location: Hariyala, Kheda, Gujarat
- Estimated amount: ₹30.13 crores
3. General Corporate Purposes
- Remaining funds will be used to support overall business operations and future growth.
Amanta Healthcare IPO Reservations
Amanta Healthcare IPO reservations to different investors are:
- For QIBs: Not more than 50% of the Net Issue
- For NIIs: Not less than 15% of the Net Issue
- For Retail Investors: Not less than 35% of the Net Issue
Amanta Healthcare IPO Lot Size
Amanta Healthcare IPO lot size is 119 shares, wherein bidding can be done in multiples. The minimum amount that each category of investor needs to bid in this IPO is:
| Feature | Green Bonds | Traditional Bonds | Sustainability-Linked Bonds (SLBs) |
|---|---|---|---|
| Use of proceeds | Only green projects | Any business usage | General or ESG-linked |
| Third-party review | Required in many jurisdictions | Not mandatory | Often required |
| Coupon adjustment | Fixed | Fixed | Variable based on sustainability targets |
| Reporting | Transparent & periodic | Standard financial reports | Linked to ESG performance metrics |
| Investor appeal | ESG-focused investors | General fixed-income investors | Both ESG & yield seekers |
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Amanta Healthcare IPO Details: Promoter Holding
The promoters of Amanta Healthcare Limited are Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendra Kumar Patel, and Milcent Appliances Private Limited.
Amanta Healthcare Limited: Company Overview
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of sterile liquid products.
The company primarily specialises in parenteral formulations, which are packaged using advanced technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) to maintain high product quality and safety standards. Alongside pharmaceuticals, Amanta also manufactures medical devices, strengthening its position as a trusted healthcare solutions provider.
Product Portfolio
The company’s product portfolio includes fluid therapy formulations such as IV fluids, diluents, ophthalmic solutions, and respiratory care products. It also offers irrigation solutions, eye lubricants, and first-aid products, addressing a variety of healthcare needs across different therapeutic segments.
Amanta markets its products through three primary business units: national sales, international sales, and product partnerships with several Indian and global pharmaceutical companies.
Manufacturing Strength
Amanta Healthcare manufactures over 45 generic products, marketed under its own brands in India through a robust network of 320 distributors and stockists.
Internationally, the company has built a significant presence in regions such as Africa, Latin America, UK, and other global markets. Its products are registered in 19 countries and, during Fiscal 2025, the company successfully exported branded products to 21 countries, complying with various regulatory standards and strengthening its global reach.
As of March 31, 2025, Amanta Healthcare employs 1,718 professionals across its manufacturing units, formulation and development facilities, and quality laboratories.
Key Strengths
The company’s strength lies in its large-scale manufacturing capabilities, which enable it to deliver high-quality products in compliance with stringent pharmacological standards.
A well-established domestic and international marketing network supports its growth. At the same time, an experienced management team, backed by a skilled and diverse workforce, continues to drive innovation, operational efficiency, and business expansion.
Amanta Healthcare IPO: Financial Performance
Amanta Healthcare Ltd. key financials for different periods are as follows:
| Particulars (in ₹ Cr) | FY25 | FY24 | YoY Change |
|---|---|---|---|
| Revenue from Operations | 274.71 | 280.34 | -2.01% |
| PAT | 10.50 | 3.63 | 189.26% |
| EBITDA | 61.05 | 58.76 | 3.90% |
| Net Cash Flow from Operating Activities | 46.62 | 58.07 | -19.72% |
| RoE (%) | 12.42% | 5.27% | 7.15% |
| RoCE (%) | 13.72% | 12.76% | 0.96% |
| Debt to Equity Ratio (x) | 2.02 | 3.10 | -1.08 |
- Amanta Healthcare reported a marginal decline of 2% in revenue, from ₹280.34 crores in FY24 to ₹274.71 crores in FY25. This change was mainly due to slight fluctuations in some product categories.
- On the other hand, profits showed significant improvement. The company’s profit after tax (PAT) surged nearly 189%, rising to ₹10.50 crores in FY25.
- EBITDA also increased modestly by 4%, reaching ₹61.05 crores, indicating that operations remained strong despite the small revenue decline.
- Cash flow from operations decreased by 20% to ₹46.62 crores in FY25.
- Return on equity (RoE) more than doubled to 12.42%, while the return on capital employed (RoCE) increased to 13.72%. This reflects better profitability and effective use of capital.
- The debt-to-equity ratio improved to 2.02, indicating stronger financial discipline and lower leverage.
Amanta Healthcare IPO Peer Comparison
Here is the competitor analysis of the Amanta Healthcare:
| Company Name (FY25) | EPS (Basic ₹) | P/E (x) | RoNW (%) |
|---|---|---|---|
| Amanta Healthcare Limited | 3.71 | 34.59 | 10.89 |
| Denis Chem Lab Limited | 5.82 | 15.92 | 9.49 |
- Amanta Healthcare Limited’s EPS is ₹3.71 and is slightly lower than its only peer, Denis Chem Lab Limited.
- Its pre-IPO PE ratio is 34.59 and is higher than the competitor’s PE ratio, meaning slightly expensive valuations.
- RONW of Amanta Healthcare Limited is better than its peer at 10.89%, which shows better returns on its net assets.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Amanta Healthcare IPO Risk Factors
Amanta Healthcare IPO GMP is ₹22 as of August 26, 2025 (at 16:54). It is expected to list at a 17.46% gain at a price of ₹148. However, GMP is not a safe or assured criterion to bid for an IPO. It is important to do your own analysis before investing in any IPO.
Amanta Healthcare IPO is exposed to various risk factors that can eventually affect its business and investors’ perception:
1. Single Facility Dependence
Amanta Healthcare operates mainly from a single manufacturing unit in Hariyala, Kheda, Gujarat. Any disruption caused by power failures, accidents, equipment breakdowns, or natural disasters could affect production and overall business operations.
2. Production and Quality Concerns
The company’s success depends on maintaining smooth production and strict quality standards. Delays, technical issues, or product defects could lead to order cancellations, product recalls, or client losses, which may affect revenue and reputation.
3. Litigation and Regulatory Challenges
Ongoing legal matters and strict regulatory requirements pose potential risks. Any unfavourable judgments, penalties, or non-compliance with pharmaceutical guidelines could impact the company’s financial performance and future growth plans.
For all the insights on Amanta Healthcare IPO and detailed expert advice, you can download the SMC ACE App or visit the SMC telegram channels. Take smart decisions and apply for the Amanta Healthcare IPO easily on the SMC ACE Apply by opening free demat account now.
Frequently Asked Questions – FAQs
1. What are the Amanta Healthcare IPO opening and closing dates?
Amanta Healthcare IPO will open for subscription on September 1, 2025, and close on September 3, 2025.
2. What is the price band for the Amanta Healthcare IPO?
The price band for the IPO is fixed at ₹120 to ₹126 per share, with a minimum investment of ₹14,994 for retail investors.
3. When will the Amanta Healthcare IPO allotment be finalised?
The IPO allotment is expected to be finalised on September 4, 2025, and shares will be credited to investors’ demat accounts by September 8, 2025.
4. On which stock exchanges will Amanta Healthcare IPO be listed?
IPO will be listed on both Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). The tentative listing date is September 9, 2025.
References:
https://www.amanta.co.in/public/assets/pdf/Investors/Offer-Document/Amanta-RHP-2025-26.pdf
https://www.investorgain.com/gmp/amanta-healthcare-ipo-gmp/1407/
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
